DIVISION OF HEALTH CARE FINANCING AND POLICY NEVADA MEDICAID DRUG USE REVIEW (DUR) BOARD PROPOSED PRIOR AUTHORIZATION CRITERIA

Tamiflu® (oseltamivir) and Relenza® (zanamivir) are a covered benefit of Nevada Medicaid for recipients who meet the following criteria for coverage.

1. Quantity Limitations:

Tamiflu[®] 30 mg capsule: 40 capsules/90 days Tamiflu[®] 45 mg capsule: 20 capsules/90 days Tamiflu[®] 75 mg capsule: 20 capsules/90 days

Tamiflu® 6 mg/mL suspension: 360 mL (6 bottles)/90 days

Relenza® 5 mg blister for oral inhalation: 40 blisters (2 packages)/90 days



